The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.

@article{Morgan2007TheIV,
  title={The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.},
  author={Claire Morgan and Paul D. Lewis and Rachel M Jones and Gianfilippo Bertelli and Geraldine A. Thomas and Robert C. F. Leonard},
  journal={Acta oncologica},
  year={2007},
  volume={46 5},
  pages={
          669-77
        }
}
Bisphosphonates and chemotherapy have increasingly gained favour in the treatment of metastatic hormone resistant prostate cancer. We investigated whether zoledronic acid, at a concentration found at the bone, would enhance the anti-tumour activity of docetaxel in the hormone resistant prostate cancer cell line PC-3. Cells were exposed to zoledronic acid (1 mM) in combination or in sequence with docetaxel (3 nM). Cell viability, apoptosis and markers for inhibition of the mevalonate pathway… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Lipid metabolic pathways as lung cancer therapeutic targets: A computational study

  • International journal of molecular medicine
  • 2012
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Zoledronic acid: an unending tale for an antiresorptive agent.

  • Expert opinion on pharmacotherapy
  • 2010
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED